In the last trading session, 1.46 million ImmunoPrecise Antibodies Ltd (NASDAQ:IPA) shares changed hands as the company’s beta touched 0.38. With the company’s per share price at $0.43 changed hands at $0.05 or 11.46% during last session, the market valuation stood at $19.63M. IPA’s last price was a discount, traded about -281.4% off its 52-week high of $1.64. The share price had its 52-week low at $0.27, which suggests the last value was 37.21% up since then. When we look at ImmunoPrecise Antibodies Ltd’s average trading volume, we note the 10-day average is 4.21 million shares, with the 3-month average coming to 7.76 million.
ImmunoPrecise Antibodies Ltd (NASDAQ:IPA) trade information
Instantly IPA was in green as seen at the end of in last trading. With action 14.00%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 4.20%, with the 5-day performance at 14.00% in the green. However, in the 30-day time frame, ImmunoPrecise Antibodies Ltd (NASDAQ:IPA) is -3.38% down. Looking at the short shares, we see there were 2.19 million shares sold at short interest cover period of 0.75 days.
ImmunoPrecise Antibodies Ltd (IPA) estimates and forecasts
Year-over-year growth is forecast to reach 0.92% up from the last financial year.
Consensus estimates given by 2 financial analysts project the company’s revenue in the current quarter to hit an average of 6.58M. 2 analysts are of the opinion that ImmunoPrecise Antibodies Ltd’s revenue for the current quarter will be 6.77M. The company’s revenue for the corresponding quarters a year ago was 6.22M and 6.46M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 5.85%. The estimates for the next quarter sales put growth at 4.81%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -11.23%. The 2025 estimates are for ImmunoPrecise Antibodies Ltd earnings to increase by 63.57%.
IPA Dividends
ImmunoPrecise Antibodies Ltd is expected to release its next quarterly earnings report on 2024-Dec-09.
ImmunoPrecise Antibodies Ltd (NASDAQ:IPA)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 5.27% of ImmunoPrecise Antibodies Ltd shares while 4.17% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 4.40%. There are 4.17% institutions holding the ImmunoPrecise Antibodies Ltd stock share, with INGALLS & SNYDER LLC the top institutional holder. As of 2024-06-30, the company held 5.0209% of the shares, roughly 1.3 million IPA shares worth $1.31 million.
RENAISSANCE TECHNOLOGIES LLC holds the second largest percentage of outstanding shares, with 0.2477% or 63910.0 shares worth $64549.0 as of 2024-06-30.
With 10.67 shares estimated at $4576.0 under it, the former controlled 0.04% of total outstanding shares.
